A Phase 1 interventional study of Deucravacitinib in Healthy Participants, sponsored by Bristol-Myers Squibb. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-07-02.
Sponsored by Bristol-Myers Squibb · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to identify drug levels of gastro-retentive (GR) formulations which prolong retaining time in the stomach of deucravacitinib (BMS-986165) in Healthy Participants.
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Deucravacitinib
Drug: Deucravacitinib
Specified dose on specified days
Also known as: BMS-986165
Maximum observed plasma concentration (Cmax)
Time frame: Up to approximately 5 days
Concentration at 24 hours post dose (C24)
Time frame: Up to approximately 5 days
Area under the concentration-time curve from time zero to time of last quantifiable concentration [AUC(0-T)]
Time frame: Up to approximately 5 days
Incidence of adverse events (AEs)
Time frame: Up to approximately 1 month
Incidence of serious adverse events (SAEs)
Time frame: Up to approximately 1 month
Incidence of AEs leading to discontinuation
Time frame: Up to approximately 1 month
Incidence of participants with vital sign abnormalities
Time frame: Up to approximately 1 month
Incidence of participants with electrocardiogram (ECG) abnormalities
Time frame: Up to approximately 1 month
Incidence of participants with physical examinations abnormalities
Time frame: Up to approximately 1 month
Incidence of participants with clinical laboratory abnormalities
Time frame: Up to approximately 1 month
Time of maximum observed concentration (Tmax)
Time frame: Up to approximately 5 days
Apparent terminal plasma half-life (T-HALF)
Time frame: Up to approximately 5 days
Apparent total body clearance (CLT/F)
Time frame: Up to approximately 5 days
Plan to share: No — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at: https://www.bms.com/researchers-and-partners/clinical-trials-and research/disclosurecommitment.html
Ran from Oct 2024 to primary completion in Jun 2025, 8 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Deucravacitinib